Pfizer Responds To FDA Over Geodon Clinical Trial

Law360, New York (April 21, 2010, 6:44 PM EDT) -- On the heels of the U.S. Food and Drug Administration's warning over Pfizer Inc.'s repeated failure to properly monitor a trial of the bipolar disorder and schizophrenia drug Geodon, the drugmaker has said it will provide the agency with information on improvements it has already made.

Pfizer will be outlining new measures it has put in place for conducting clinical trials, the company said in a statement Tuesday, the same day the FDA published its April 9 warning letter to the company.

The FDA's letter concerned...
To view the full article, register now.